| 0 |
CANNABIS INTERACTION |
1 |
0.0769 |
| 1 |
INCREASED LIVER STIFFNESS |
1 |
0.0294 |
| 2 |
BLOOD ERYTHROPOIETIN INCREASED |
1 |
0.0101 |
| 3 |
MALE GENITAL ATROPHY |
1 |
0.0093 |
| 4 |
PRODUCT ADVERTISING ISSUE |
1 |
0.0047 |
| 5 |
IMMUNE-MEDIATED MYASTHENIA GRAVIS |
1 |
0.0031 |
| 6 |
PENILE ULCERATION |
1 |
0.0031 |
| 7 |
GASTROINTESTINAL MICROORGANISM OVERGROWTH |
1 |
0.0028 |
| 8 |
BONE DENSITY INCREASED |
1 |
0.0025 |
| 9 |
TACHYARRHYTHMIA |
6 |
0.0024 |
| 10 |
HEART FAILURE WITH REDUCED EJECTION FRACTION |
1 |
0.0019 |
| 11 |
POSITRON EMISSION TOMOGRAM ABNORMAL |
1 |
0.0014 |
| 12 |
DYSBIOSIS |
1 |
0.0012 |
| 13 |
URGE INCONTINENCE |
1 |
0.0011 |
| 14 |
POSTICTAL STATE |
1 |
0.0010 |
| 15 |
FAECES PALE |
2 |
0.0009 |
| 16 |
TORSADE DE POINTES |
6 |
0.0008 |
| 17 |
SELF-MEDICATION |
3 |
0.0007 |
| 18 |
RED BLOOD CELL COUNT INCREASED |
2 |
0.0007 |
| 19 |
H1N1 INFLUENZA |
1 |
0.0007 |
| 20 |
DIABETIC FOOT INFECTION |
1 |
0.0007 |
| 21 |
HORDEOLUM |
3 |
0.0007 |
| 22 |
HEPATIC NEOPLASM |
2 |
0.0006 |
| 23 |
HYPERAMMONAEMIA |
3 |
0.0006 |
| 24 |
GASTRIC DILATATION |
1 |
0.0006 |
| 25 |
SEIZURE LIKE PHENOMENA |
1 |
0.0006 |
| 26 |
INTRA-ABDOMINAL FLUID COLLECTION |
1 |
0.0006 |
| 27 |
CARCINOEMBRYONIC ANTIGEN INCREASED |
1 |
0.0005 |
| 28 |
NASAL SEPTUM DEVIATION |
1 |
0.0005 |
| 29 |
BLOOD TESTOSTERONE INCREASED |
1 |
0.0005 |
| 30 |
HAEMORRHAGE URINARY TRACT |
1 |
0.0004 |
| 31 |
PELVIC FRACTURE |
3 |
0.0004 |
| 32 |
IMMUNE-MEDIATED MYOSITIS |
1 |
0.0004 |
| 33 |
UPPER RESPIRATORY TRACT CONGESTION |
1 |
0.0003 |
| 34 |
PULMONARY PAIN |
1 |
0.0003 |
| 35 |
HYPERCAPNIA |
1 |
0.0003 |
| 36 |
MUSCULOSKELETAL CHEST PAIN |
5 |
0.0003 |
| 37 |
BLOOD BLISTER |
1 |
0.0003 |
| 38 |
ANTINUCLEAR ANTIBODY POSITIVE |
1 |
0.0003 |
| 39 |
NEOPLASM RECURRENCE |
1 |
0.0003 |
| 40 |
ACUTE HEPATIC FAILURE |
4 |
0.0003 |
| 41 |
CERVIX CARCINOMA |
1 |
0.0003 |
| 42 |
MUSCLE FATIGUE |
1 |
0.0002 |
| 43 |
POOR PERIPHERAL CIRCULATION |
1 |
0.0002 |
| 44 |
BONE CANCER |
1 |
0.0002 |
| 45 |
TONGUE DISCOLOURATION |
1 |
0.0002 |
| 46 |
SUSPECTED OFF LABEL USE |
1 |
0.0002 |
| 47 |
LOCALISED OEDEMA |
1 |
0.0002 |
| 48 |
DRUG EFFECTIVE FOR UNAPPROVED INDICATION |
6 |
0.0002 |
| 49 |
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED |
1 |
0.0002 |
| 50 |
FAECES DISCOLOURED |
4 |
0.0002 |
| 51 |
COAGULOPATHY |
3 |
0.0002 |
| 52 |
PERIORBITAL SWELLING |
1 |
0.0002 |
| 53 |
MOUTH SWELLING |
1 |
0.0002 |
| 54 |
HYPERVENTILATION |
1 |
0.0002 |
| 55 |
ENERGY INCREASED |
1 |
0.0002 |
| 56 |
ELECTROCARDIOGRAM QT PROLONGED |
6 |
0.0002 |
| 57 |
PIGMENTATION DISORDER |
1 |
0.0002 |
| 58 |
SCOLIOSIS |
1 |
0.0002 |
| 59 |
POISONING |
2 |
0.0002 |
| 60 |
HAEMOGLOBIN ABNORMAL |
1 |
0.0002 |
| 61 |
ERUCTATION |
3 |
0.0002 |
| 62 |
UNRESPONSIVE TO STIMULI |
4 |
0.0002 |
| 63 |
SOMNAMBULISM |
1 |
0.0002 |
| 64 |
WRONG PRODUCT ADMINISTERED |
1 |
0.0001 |
| 65 |
PROSTATIC SPECIFIC ANTIGEN INCREASED |
2 |
0.0001 |
| 66 |
ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE |
1 |
0.0001 |
| 67 |
ALTERED STATE OF CONSCIOUSNESS |
3 |
0.0001 |
| 68 |
FAECES SOFT |
1 |
0.0001 |
| 69 |
ACIDOSIS |
1 |
0.0001 |
| 70 |
DRUG-INDUCED LIVER INJURY |
4 |
0.0001 |
| 71 |
BLOOD PRESSURE FLUCTUATION |
3 |
0.0001 |
| 72 |
SECOND PRIMARY MALIGNANCY |
1 |
0.0001 |
| 73 |
EOSINOPHIL COUNT INCREASED |
1 |
0.0001 |
| 74 |
MUSCLE STRAIN |
1 |
0.0001 |
| 75 |
JAUNDICE |
3 |
0.0001 |
| 76 |
LOSS OF LIBIDO |
1 |
0.0001 |
| 77 |
FREQUENT BOWEL MOVEMENTS |
3 |
0.0001 |
| 78 |
NERVE COMPRESSION |
1 |
0.0001 |
| 79 |
HEPATIC STEATOSIS |
2 |
0.0001 |
| 80 |
HEPATIC ENCEPHALOPATHY |
1 |
0.0001 |
| 81 |
HOT FLUSH |
8 |
0.0001 |
| 82 |
MULTIPLE ORGAN DYSFUNCTION SYNDROME |
3 |
0.0001 |
| 83 |
HEPATOMEGALY |
1 |
0.0001 |
| 84 |
URINARY INCONTINENCE |
3 |
0.0001 |
| 85 |
MOTOR DYSFUNCTION |
1 |
0.0001 |
| 86 |
INITIAL INSOMNIA |
1 |
0.0001 |
| 87 |
PRODUCT ODOUR ABNORMAL |
1 |
0.0001 |
| 88 |
POOR QUALITY PRODUCT ADMINISTERED |
1 |
0.0001 |
| 89 |
BLOOD GLUCOSE FLUCTUATION |
1 |
0.0001 |
| 90 |
THERAPEUTIC RESPONSE SHORTENED |
3 |
0.0001 |
| 91 |
HEPATOTOXICITY |
2 |
0.0001 |
| 92 |
GLOSSODYNIA |
2 |
0.0001 |
| 93 |
CHROMATURIA |
2 |
0.0001 |
| 94 |
EYE INFECTION |
1 |
0.0001 |
| 95 |
FLATULENCE |
5 |
0.0001 |
| 96 |
ENCEPHALOPATHY |
2 |
0.0001 |
| 97 |
INJECTION SITE MASS |
3 |
0.0001 |
| 98 |
PULMONARY CONGESTION |
1 |
0.0001 |
| 99 |
BLOOD BILIRUBIN INCREASED |
2 |
0.0001 |
| 100 |
LIMB INJURY |
2 |
0.0001 |
| 101 |
OSTEOPOROSIS |
3 |
0.0001 |
| 102 |
BLOOD TEST ABNORMAL |
1 |
0.0001 |
| 103 |
INTENTIONAL DOSE OMISSION |
2 |
0.0001 |
| 104 |
HYPERSOMNIA |
2 |
0.0001 |
| 105 |
PULMONARY MASS |
1 |
0.0001 |
| 106 |
THYROID DISORDER |
1 |
0.0001 |
| 107 |
BLOOD LACTATE DEHYDROGENASE INCREASED |
1 |
0.0001 |
| 108 |
SCIATICA |
1 |
0.0001 |
| 109 |
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES |
3 |
0.0001 |
| 110 |
SENSORY DISTURBANCE |
1 |
0.0001 |
| 111 |
METASTASES TO BONE |
1 |
0.0001 |
| 112 |
ANGER |
2 |
0.0001 |
| 113 |
MALIGNANT NEOPLASM PROGRESSION |
6 |
0.0001 |
| 114 |
MUSCULOSKELETAL DISCOMFORT |
1 |
0.0001 |
| 115 |
BLOOD TRIGLYCERIDES INCREASED |
1 |
0.0001 |
| 116 |
HEAD DISCOMFORT |
1 |
0.0001 |
| 117 |
GOUT |
1 |
0.0001 |
| 118 |
TOOTHACHE |
1 |
0.0001 |
| 119 |
HEPATIC CIRRHOSIS |
1 |
0.0001 |
| 120 |
NEUROPATHY PERIPHERAL |
5 |
0.0001 |
| 121 |
DYSPHONIA |
3 |
0.0001 |
| 122 |
KIDNEY INFECTION |
1 |
0.0001 |
| 123 |
DISORIENTATION |
2 |
0.0001 |
| 124 |
STOMATITIS |
3 |
0.0000 |
| 125 |
ACCIDENTAL EXPOSURE TO PRODUCT |
5 |
0.0000 |
| 126 |
PULMONARY HYPERTENSION |
1 |
0.0000 |
| 127 |
EATING DISORDER |
1 |
0.0000 |
| 128 |
IRRITABLE BOWEL SYNDROME |
1 |
0.0000 |
| 129 |
LIVER FUNCTION TEST INCREASED |
1 |
0.0000 |
| 130 |
RHINORRHOEA |
3 |
0.0000 |
| 131 |
WHITE BLOOD CELL COUNT DECREASED |
5 |
0.0000 |
| 132 |
GAMMA-GLUTAMYLTRANSFERASE INCREASED |
1 |
0.0000 |
| 133 |
RASH MACULO-PAPULAR |
1 |
0.0000 |
| 134 |
LOCALISED INFECTION |
1 |
0.0000 |
| 135 |
HYPOGLYCAEMIA |
2 |
0.0000 |
| 136 |
PRESYNCOPE |
1 |
0.0000 |
| 137 |
LIVER INJURY |
1 |
0.0000 |
| 138 |
ERECTILE DYSFUNCTION |
1 |
0.0000 |
| 139 |
SKIN ULCER |
1 |
0.0000 |
| 140 |
HAEMATOMA |
1 |
0.0000 |
| 141 |
ABDOMINAL DISTENSION |
4 |
0.0000 |
| 142 |
ASPARTATE AMINOTRANSFERASE INCREASED |
2 |
0.0000 |
| 143 |
INJECTION SITE BRUISING |
3 |
0.0000 |
| 144 |
SKIN LESION |
1 |
0.0000 |
| 145 |
ABNORMAL DREAMS |
1 |
0.0000 |
| 146 |
FEELING COLD |
1 |
0.0000 |
| 147 |
PRODUCT DOSE OMISSION IN ERROR |
1 |
0.0000 |
| 148 |
PAIN IN JAW |
1 |
0.0000 |
| 149 |
INTERNATIONAL NORMALISED RATIO INCREASED |
1 |
0.0000 |
| 150 |
ANGINA PECTORIS |
1 |
0.0000 |
| 151 |
SEIZURE |
4 |
0.0000 |
| 152 |
INTENTIONAL PRODUCT MISUSE |
3 |
0.0000 |
| 153 |
RESPIRATORY DISORDER |
1 |
0.0000 |
| 154 |
BLOOD POTASSIUM DECREASED |
1 |
0.0000 |
| 155 |
LACRIMATION INCREASED |
1 |
0.0000 |
| 156 |
ALANINE AMINOTRANSFERASE INCREASED |
2 |
0.0000 |
| 157 |
LIMB DISCOMFORT |
1 |
0.0000 |
| 158 |
MOOD SWINGS |
1 |
0.0000 |
| 159 |
METABOLIC ACIDOSIS |
1 |
0.0000 |
| 160 |
AMNESIA |
2 |
0.0000 |
| 161 |
STAPHYLOCOCCAL INFECTION |
1 |
0.0000 |
| 162 |
BACK PAIN |
7 |
0.0000 |
| 163 |
LIP SWELLING |
1 |
0.0000 |
| 164 |
ABDOMINAL DISCOMFORT |
5 |
0.0000 |
| 165 |
FLUSHING |
3 |
0.0000 |
| 166 |
HAEMATURIA |
1 |
0.0000 |
| 167 |
PRODUCT USE IN UNAPPROVED INDICATION |
7 |
0.0000 |
| 168 |
MUSCLE SPASMS |
5 |
0.0000 |
| 169 |
WEIGHT INCREASED |
6 |
0.0000 |
| 170 |
ASTHENIA |
10 |
0.0000 |
| 171 |
DYSPNOEA EXERTIONAL |
1 |
0.0000 |
| 172 |
WHITE BLOOD CELL COUNT INCREASED |
1 |
0.0000 |
| 173 |
DECREASED APPETITE |
6 |
0.0000 |
| 174 |
FATIGUE |
20 |
0.0000 |
| 175 |
ALOPECIA |
5 |
0.0000 |
| 176 |
ABNORMAL BEHAVIOUR |
1 |
0.0000 |
| 177 |
DYSKINESIA |
1 |
0.0000 |
| 178 |
POLLAKIURIA |
1 |
0.0000 |
| 179 |
TOXICITY TO VARIOUS AGENTS |
4 |
0.0000 |
| 180 |
INSOMNIA |
6 |
0.0000 |
| 181 |
TACHYCARDIA |
2 |
0.0000 |
| 182 |
THERAPY NON-RESPONDER |
1 |
0.0000 |
| 183 |
NO ADVERSE EVENT |
4 |
0.0000 |
| 184 |
NEPHROLITHIASIS |
1 |
0.0000 |
| 185 |
SKIN DISCOLOURATION |
1 |
0.0000 |
| 186 |
CHEST PAIN |
4 |
0.0000 |
| 187 |
HYPERSENSITIVITY |
4 |
0.0000 |
| 188 |
RENAL DISORDER |
1 |
0.0000 |
| 189 |
BLOOD CHOLESTEROL INCREASED |
1 |
0.0000 |
| 190 |
PRODUCTIVE COUGH |
1 |
0.0000 |
| 191 |
DIARRHOEA |
13 |
0.0000 |
| 192 |
SYNCOPE |
2 |
0.0000 |
| 193 |
ACUTE KIDNEY INJURY |
3 |
0.0000 |
| 194 |
CHEST DISCOMFORT |
2 |
0.0000 |
| 195 |
THERAPY CESSATION |
1 |
0.0000 |
| 196 |
HAEMOGLOBIN DECREASED |
2 |
0.0000 |
| 197 |
ABDOMINAL PAIN UPPER |
4 |
0.0000 |
| 198 |
INFLAMMATION |
1 |
0.0000 |
| 199 |
DRUG INTERACTION |
3 |
0.0000 |
| 200 |
PLATELET COUNT DECREASED |
2 |
0.0000 |
| 201 |
CONSTIPATION |
4 |
0.0000 |
| 202 |
ANAPHYLACTIC REACTION |
1 |
0.0000 |
| 203 |
WEIGHT DECREASED |
5 |
0.0000 |
| 204 |
NECK PAIN |
1 |
0.0000 |
| 205 |
THROMBOCYTOPENIA |
2 |
0.0000 |
| 206 |
BLISTER |
1 |
0.0000 |
| 207 |
MUSCULAR WEAKNESS |
2 |
0.0000 |
| 208 |
PALPITATIONS |
2 |
0.0000 |
| 209 |
BONE PAIN |
1 |
0.0000 |
| 210 |
SURGERY |
1 |
0.0000 |
| 211 |
NASAL CONGESTION |
1 |
0.0000 |
| 212 |
FEELING ABNORMAL |
4 |
0.0000 |
| 213 |
JOINT SWELLING |
2 |
0.0000 |
| 214 |
OEDEMA PERIPHERAL |
2 |
0.0000 |
| 215 |
OFF LABEL USE |
14 |
0.0000 |
| 216 |
PRURITUS |
6 |
0.0000 |
| 217 |
FEBRILE NEUTROPENIA |
1 |
0.0000 |
| 218 |
FALL |
5 |
0.0000 |
| 219 |
HYPOTENSION |
3 |
0.0000 |
| 220 |
HEPATIC ENZYME INCREASED |
1 |
0.0000 |
| 221 |
ARTHRALGIA |
6 |
0.0000 |
| 222 |
HEADACHE |
9 |
0.0000 |
| 223 |
BURNING SENSATION |
1 |
0.0000 |
| 224 |
DYSPNOEA |
8 |
0.0000 |
| 225 |
RESPIRATORY FAILURE |
1 |
0.0000 |
| 226 |
PRODUCT DOSE OMISSION ISSUE |
4 |
0.0000 |
| 227 |
PAIN IN EXTREMITY |
4 |
0.0000 |
| 228 |
EPISTAXIS |
1 |
0.0000 |
| 229 |
UNEVALUABLE EVENT |
1 |
0.0000 |
| 230 |
PERIPHERAL SWELLING |
2 |
0.0000 |
| 231 |
ABDOMINAL PAIN |
3 |
0.0000 |
| 232 |
GASTROOESOPHAGEAL REFLUX DISEASE |
1 |
0.0000 |
| 233 |
TREATMENT FAILURE |
1 |
0.0000 |
| 234 |
SKIN EXFOLIATION |
1 |
0.0000 |
| 235 |
MYALGIA |
2 |
0.0000 |
| 236 |
BALANCE DISORDER |
1 |
0.0000 |
| 237 |
INTENTIONAL PRODUCT USE ISSUE |
1 |
0.0000 |
| 238 |
COVID-19 |
2 |
0.0000 |
| 239 |
ADVERSE DRUG REACTION |
1 |
0.0000 |
| 240 |
NASOPHARYNGITIS |
2 |
0.0000 |
| 241 |
PRODUCT USE ISSUE |
2 |
0.0000 |
| 242 |
PULMONARY EMBOLISM |
1 |
0.0000 |
| 243 |
CONTUSION |
1 |
0.0000 |
| 244 |
DYSPEPSIA |
1 |
0.0000 |
| 245 |
NAUSEA |
8 |
0.0000 |
| 246 |
DIZZINESS |
5 |
0.0000 |
| 247 |
CONDITION AGGRAVATED |
3 |
0.0000 |
| 248 |
INJECTION SITE PAIN |
3 |
0.0000 |
| 249 |
ILLNESS |
1 |
0.0000 |
| 250 |
HYPERTENSION |
2 |
0.0000 |
| 251 |
PNEUMONIA |
3 |
0.0000 |
| 252 |
MALAISE |
4 |
0.0000 |
| 253 |
VOMITING |
4 |
0.0000 |
| 254 |
EMOTIONAL DISTRESS |
1 |
0.0000 |
| 255 |
PAIN |
5 |
0.0000 |
| 256 |
VISION BLURRED |
1 |
0.0000 |
| 257 |
ANXIETY |
2 |
0.0000 |
| 258 |
INFECTION |
1 |
0.0000 |
| 259 |
HYPOAESTHESIA |
1 |
0.0000 |
| 260 |
BLOOD PRESSURE INCREASED |
1 |
0.0000 |
| 261 |
HOSPITALISATION |
1 |
0.0000 |
| 262 |
URTICARIA |
1 |
0.0000 |
| 263 |
CEREBROVASCULAR ACCIDENT |
1 |
0.0000 |
| 264 |
URINARY TRACT INFECTION |
1 |
0.0000 |
| 265 |
OVERDOSE |
1 |
0.0000 |
| 266 |
RASH |
2 |
0.0000 |
| 267 |
DEPRESSION |
1 |
0.0000 |
| 268 |
INCORRECT DOSE ADMINISTERED |
1 |
0.0000 |
| 269 |
DRUG INEFFECTIVE |
5 |
0.0000 |
| 270 |
COUGH |
1 |
0.0000 |
| 271 |
DEATH |
2 |
0.0000 |